Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nifedipine GITS and Candesartan Cilexetil FDC in Essential Hypertension
NCT02047019Phase 3Withdrawn
- Sponsor
- Bayer
- Start
- Dec 2017
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of BAY 98-7106 in essential hypertension, sponsored by Bayer. Planned start Dec 2017; status: withdrawn.
02
Drugs
BAY 98-7106
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT02047019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02047019.